Advertisement

BMC Geriatrics

, 18:301 | Cite as

Use of over the counter products in older cardiovascular patients admitted to a tertiary care center in USA

  • Marwan Sheikh-Taha
  • Hani Dimassi
Open Access
Research article
  • 131 Downloads
Part of the following topical collections:
  1. Health services research

Abstract

Background

In recent years there has been a substantial increase in the use of over-the-counter (OTC) products around the world. While they are assumed to be safe by consumers, they can potentially lead to adverse effects and drug interactions particularly in older adults.

Methods

We assessed the patterns of OTC products used by older adults admitted to the cardiology service in a tertiary care medical center in the USA over a three month period. We conducted a retrospective chart review where older adults with cardiovascular diseases (CVD) who were taking at least one OTC product at home were included.

Results

Out of 404 patients who were admitted to the cardiology service, 281 (69.6%) were taking OTC products. Patients were taking a total of 659 OTC products; mean of 2.35 ± 1.57 and the range varied from 1 to 9 products. The most commonly used products were vitamins (37.3%), followed by laxatives (17%), minerals (13.6%), stomach acid reducers (9%), and analgesics (3.6%). OTC users were found to be suffering from more comorbidities and received more prescription medications as compared to non-users. Gender and age did not have an impact on the use of OTC products while patients with atrial fibrillation, sleep apnea and gastro-esophageal reflux disease were more likely to use OTC products.

Conclusion

Use of OTC products is quite frequent in older adults with CVD in our study. Clinicians should ask about OTC product usage and counsel patients about the risks and benefits associated with their use.

Keywords

Over the counter medications Cardiovascular disease Geriatrics 

Abbreviations

A Fib

Atrial fibrillation

AGS

American Geriatrics Society

CAD

Coronary artery disease

CHF

Congestive heart failure

CVD

Cardiovascular disease

GERD

Gastro-esophageal reflux disease

OTC

Over the counter

PEG

Polyethylene glycol

PPIs

Proton pump inhibitors

Background

The American Heart Association estimates that 92.1 million US adults have at least 1 type of cardiovascular disease (CVD) and by 2030, 43.9% of the US population is projected to have some form of CVD [1]. CVD imposes an enormous burden in terms of disability, mortality, morbidity, functional decline, and healthcare costs specifically in older adults as there is a marked increase in the incidence and prevalence of CVD in this age group [1]. In recent years, there has been an increasing prevalence of using over-the-counter (OTC) products, including nonprescription medications, vitamins, minerals, and herbal products [2, 3]. These products can be purchased without a prescription for therapeutic benefit and preventive healthcare purposes. While OTC products are assumed to be safe by consumers, they can potentially lead to adverse effects and drug interactions particularly in the older adults due to polypharmacy and the changes in renal and hepatic function associated with older age. Furthermore, herbal use is independently associated with low medication adherence among patients with CVD [4].

In the United States, a direct mail out questionnaire showed the prevalence of multivitamin use to be 68% among outpatient with CVD [5]. Additionally, in elderly patients with heart failure, routine use of OTC medications was reported to be 93.3% while herbal therapy use was 11.5% [6]. In Canada, the use of OTC drugs in patients with CVD was reported to be 67% [7]. In Italy, OTC drug use (excluding vitamins and nutritional supplements) among heart failure patients was 75.8% [8].

While the number of products that can be purchased from pharmacies without the need for a prescription is increasing, this may encourage patients to utilize more of these products which are indeed a therapeutic option, but only if used properly under the guidance of a healthcare professional. Unfortunately, physicians are frequently unaware of their patients’ OTC product use because they do not ask patients, and/or patients do not disclose use of OTC products [9, 10].

Literature regarding OTC products use in patients with CVD is limited. Hence, we conducted this study to describe the pattern of use of OTC products in older adults with CVD admitted to a large tertiary care hospital. We also sought to identify variables associated with their use.

Methods

A retrospective chart review was conducted where all patients with CVD (including coronary heart disease, peripheral arterial disease, heart failure, valvular heart disease, arrhythmia, and stroke) admitted to the cardiology service at a tertiary care center, Huntsville Hospital, Alabama, USA, from March to May 2016 were assessed. Inclusion criteria were patient age of 65 years and above, taking at least one OTC product at home (including nonprescription medications, vitamins, minerals, and herbal products), history of CVD, and admission to the cardiology service. If a patient was admitted more than once during the study period, the first admission was considered the index visit. Data collected from medical records were analyzed using SPSS version v23 (BM SPSS Statistics for Windows, Version 24.0. Armonk, NY: IBM Corp). Data collected include demographic characteristics, number and types of comorbidities, OTC products used, and number of prescription medications used. Descriptive statistics were expressed as mean and standard deviations for numerical data, and frequencies and percentages for categorical data. Differences in means between OTC users and non-users were assessed using the independent t test, while differences in proportions were tested with the Pearson’s Chi-square. Statistical significance was evaluated at the 0.05 significance level. The cohort in this study was also assessed for the use of pain medications [11].

Results

A total of 404 older patients with a history of CVD were admitted to the cardiology service during the study period out of which 281 (69.6%) were taking at least one OTC product and were included in the study. Included patients had a mean age of 77.0 ± 7.5 years and 50.2% were males. Table 1 shows the characteristics of included patients. The most common comorbidities were hypertension (75.1%), followed by dyslipidemia (52.7%), coronary artery disease (CAD) (47.7%), and congestive heart failure (CHF) (45.9%). Table 2 shows the comorbidities with prevalence greater than 5% among OTC users. The average number of prescription products utilized by patients was 10.6 ± 3.7. Patients were taking a total of 659 OTC products; mean of 2.35 ± 1.57 and the range varied widely from 1 to 9 products. The most commonly used products were vitamins (37.3%), followed by laxatives (17%), minerals (13.6%), stomach acid reducers (9%), and analgesics (3.6%). The usage of specific single entity vitamin product was most commonly vitamin D, followed by vitamin B12, folic acid, and vitamin C. Table 3 describes the types of OTC products used. OTC users were found to be suffering from more comorbidities and received more prescription medications as compared to non-users (both p-values < 0.001) (Table 4). While gender and age did not have an impact on the use of OTC products, use of OTC products varied with history of certain medical conditions; patients with a history of atrial fibrillation (A Fib), sleep apnea, and gastro-esophageal reflux disease (GERD) were more likely to use OTC products (Table 5).
Table 1

Descriptive characteristics of OTC users

Number of OTC products

N

%

1

105

37.4

2

79

28.1

3

48

17.1

4

20

7.1

5

14

5

6

8

2.8

7

3

1.1

8

3

1.1

9

1

0.4

Mean (SD)

2.35

(1.57)

Median

2.00

 

Age group

 65–69

56

19.9

 70–74

58

20.6

 75–79

56

19.9

 80–84

60

21.4

 85–89

32

11.4

 90+

19

6.8

Mean (SD)

77.0

(7.5)

Median

76.0

 

Gender

  

 Males

141

50.2

 Females

140

49.8

Number of comorbidities

 1

1

0.4

 2

2

0.7

 3

16

5.7

 4

52

18.5

 5

39

13.9

 6

37

13.2

 7

42

14.9

 8

40

14.2

 9

29

10.3

 10

9

3.2

 11

4

1.4

 12

4

1.4

 13

1

0.4

 14

3

1.1

 15

1

0.4

 16

1

0.4

Mean (SD)

6.5

(2.4)

Median

6.0

 
Table 2

Comorbidities with prevalence greater than 5% among OTC users

 

N

%

Hypertension

211

75.1

Dyslipidemia

148

52.7

CAD

134

47.7

CHF

129

45.9

Diabetes mellitus

108

38.4

A Fib/flutter

106

37.7

CKD

89

31.7

COPD

61

21.7

Hypothyroidism

59

21.0

Cancer

55

19.6

Arthritis

54

19.2

GERD

54

19.2

Cardiac valve disease

46

16.4

BPH

45

16

CVA

42

14.9

PVD

36

12.8

Sleep apnea

34

12.1

Anemia

34

12.1

Gout

28

10

Depression

26

9.3

Pulmonary hypertension

24

8.5

Anxiety

23

8.2

GI bleed/ulcer

22

7.8

DVT /PE

22

7.8

Asthma

21

7.5

Obesity

21

7.5

Dementia

20

7.1

Neuropathy

19

6.8

CAD: coronary artery disease; CHF: congestive heart failure; A Fib: atrial fibrillation; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; GERD: gastro-esophageal reflux disease; BPH: benign prostatic hyperplasia; CVA: cerebrovascular accident; PVD: peripheral vascular disease; GI: gastrointestinal; DVT: deep venous thrombosis; S: pulmonary embolism

Table 3

Type of OTC products used by patients

Type of OTC Product

No (%)

Vitamins

246 (37.3%)

 Vitamin D

94

 Multi-vitamins

67

 Vitamin B12

37

 Folic acid

16

 Vitamin C

8

 Biotin

8

 Vitamin B complex

7

 Vitamin E

3

 Vitamin B3 (niacin)

3

 Vitamin B1

2

 Vitamin B6

1

Laxatives

112 (17%)

 Docusate

60

 Polyethylene glycol (PEG)

34

 Senna

8

 Psyllium

6

 Bisacodyl

4

Minerals

90 (13.6%)

 Iron

33

 Calcium

29

 Magnesium

15

 Potassium

11

 Zinc

2

Stomach acid reducers

59 (9%)

 Proton pump inhibitors (PPIs)

23

 H2 antagonists

36

Analgesics

24 (3.6%)

Acetaminophen

17

Nonsteroidal anti-inflammatory drugs

7

Omega-3-acid

19 (2.9%)

Antihistamines

18 (2.7%)

 Loratadine

11

 Diphenhydramine

7

Coenzyme Q10

11 (1.7%)

Probiotics

11 (1.7%)

Other

50 (7.6%)

 Fluticasone nasal spray

10

 Guaifenesin

10

 Melatonin

9

 Nicotine

8

 Glucosamine

4

 Chondroitin

3

 Cranberry

3

 Artificial tears

3

Table 4

Characteristics of OTC users vs non users

 

NON USERS OF OTC

USERS OF OTC

N

Mean

SD

N

Mean

SD

p-value

Age

123

75.7

7.1

281

77.0

7.5

0.097

No of prescription meds

123

8.4

3.7

281

10.6

3.7

< 0.001

No of comorbidities

123

5.2

2.1

281

6.5

2.4

< 0.001

Table 5

Mean of OTC products used by users characteristics

 

N

Mean

SD

p-value

Age groups

 65–69

56

2.23

1.477

0.403

 70–74

58

2.24

1.658

 75–79

56

2.39

1.67

 80–84

60

2.18

1.432

 85–89

32

2.66

1.45

 90+

19

2.84

1.803

Gender

 Males

141

2.22

1.455

0.178

 Females

140

2.47

1.664

A Fib

 Absent

175

2.19

1.465

0.038

 Present

106

2.59

1.695

Sleep apnea

 Absent

247

2.25

1.504

0.006

 Present

34

3.03

1.834

GERD

 Absent

227

2.22

1.464

0.015

 Present

54

2.89

1.85

Discussion

This study focused on examining the types of OTC products used by older adults with CVD and the association between use and several factors. According to our findings, OTC product use among older adults with CVD is quiet frequent. While the use of OTC and herbal products in patients with CVD across Canada was 67%, which is very similar to what we saw in our study (69.6%) [7], the methodological differences across studies, including heterogeneity in products studied, age, and the specific CVD prevent direct comparison between our study and other studies.

Vitamins were the most commonly used OTC products in our study which is similar to other studies conducted in Canada, Australia, and USA involving older adults or patients with CVD [7, 12, 13, 14, 15]. The role of vitamins A, B, C, E, biotin, and β-carotene in CVD has been explored in several randomized controlled trials and results showed that they have no role in primary or secondary prevention of CVD and may even increase mortality in patients with pre-existing late-stage atherosclerosis [16, 17, 18, 19, 20]. Hence, the evidence is still insufficient to support the role of routine use of vitamins in patients with CVD. Furthermore, the FDA has issued a warning after an increase in the number of reported adverse effects, including one death following falsely low troponin results, caused by biotin use. Many lab tests that use biotin technology, including cardiovascular diagnostic tests and hormone tests, may generate incorrect results if there is biotin in patient’s specimen which may lead to inappropriate patient management or misdiagnosis. FDA advised patients to consult their clinicians if they are taking or thinking about taking biotin or any supplements containing biotin [21].

Vitamin D was the most commonly used vitamin in our study (38.2%). Identification of vitamin D receptors in the heart and vascular endothelial cells raised interest in the potential cardiovascular effects of vitamin D. Although several epidemiological studies have suggested that persons with low blood levels of vitamin D have increased risks of heart disease, stroke, and hypertension [22, 23, 24, 25], meta-analyses and randomized controlled trials of vitamin D supplementation have failed to show cardiovascular benefits of this vitamin [26, 27].

Constipation is a common complaint in older adults and about one in six patients were on OTC laxatives in our study. Docusate was the most commonly used laxative despite the insufficient evidence to support its use in chronic constipation [28]. On the other hand, the second most commonly used laxative was polyethylene glycol (PEG), an agent with good quality evidence supporting its use in chronic constipation and is considered safe in long-term use [29, 30].

About one in ten patients used stomach acid reducers (H2 antagonists or proton pump inhibitors (PPIs)). According to the American Geriatrics Society (AGS), H2 antagonists’ doses have to be reduced due to varying levels of kidney function, a problem that is common in older adults while the PPI use beyond 8 weeks without justification should be avoided [31]. It is important that prescribers be aware of the use of stomach acid reducers in older adults and monitor their continued use to prevent the unnecessary cost, drug-drug interactions and side effects.

Non-steroidal anti-inflammatory drugs (NSAIDs) increase the risk of cardiovascular events as early as the first weeks of use, especially when used at higher doses. In addition, following NSAID use patients with heart disease or risk factors for it have a greater likelihood of heart attack or stroke than patients without these risk factors [32, 33]. In addition, the AGS recommends avoiding chronic NSAID use due to increased risk of gastrointestinal bleeding or peptic ulcer disease especially in patients on anticoagulants, or antiplatelet agents which is common in patients with CVD [31]. Patients should be counseled to take NSAIDs only if needed, at the lowest effective dose and for the shortest period of time.

A small portion of patients used herbal products. Unlike pharmaceutical products approved for the treatment of a specific disease, herbal products used by our patients have little published high quality evidence to support their use and are marketed without proof of efficacy or safety.

In our study, age and gender did not have an effect on the utilization of OTC products, which is consistent with findings from one study conducted across Canada involving adults with CVD [7]. Similarly, another study involving older adults living on the United States-Mexico border did not find any significant difference between men and women [34]. On the other hand, in a study conducted in South Australia, females as well as older adults between 65 and 79 years were more likely to use OTC products than those 80 years and older [12]. Our results suggest that some comorbidities were associated with an increased likelihood of using OTC products; A fib, sleep apnea, and GERD. Furthermore, OTC users tend to have more comorbidities and received more prescription medications as compared to non-users. These findings need to be confirmed by further studies.

Our study revealed that concurrent use of prescription and OTC products in older adults with CVD remains an important public health problem that needs to be monitored closely. Healthcare professionals need to be aware of the use of the OTC products in patients with CVD and encourage patients to report the use of such products. Furthermore, physicians and pharmacists should be aware of their potential for adverse reactions and drug interactions which is expected to be high among patients with CVD due to complex and multi drug regimens usually prescribed to this group of patients.

Our study is not without limitations. This is a retrospective chart review conducted at a single tertiary center in Alabama, USA, prevalence and types of OTC products may be different in more ethnically diverse populations. Patients may be unable to recall the OTC products they are taking due to poor health literacy, which can underestimate the prevalence of their use. In addition, incomplete documentation of the use of OTC products in patients’ chart cannot be excluded.

Conclusion

In conclusion, the use of OTC products is common in older adults with CVD. Vitamins, laxatives, minerals, and stomach acid reducers were the most commonly used products. Clinicians treating patients with CVD should ask about OTC products usage and counsel patients about the risks and benefits associated with their use.

Notes

Acknowledgements

We are immensely grateful to Huntsville Hospital’s pharmacy department for the endless help and support.

Funding

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

MST conception and design, data collection, analysis and interpretation of the data, drafting of the paper and revising it critically for intellectual content. HD analysis and interpretation of the data and revising the paper. Both authors have read and approved the final version of the manuscript.

Ethics approval and consent to participate

The study was exempted from review by Huntsville Hospital’s Institutional’s Review Committee.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.
    Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–603.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    de Souza Silva JE, Souza CA, da Silva TB, Gomes IA, de Carvalho Brito G, de Souza Araújo AA. de Lyra-Júnior DP, da Silva WB, da Silva FA. Use of herbal medicines by elderly patients: a systematic review. Arch Gerontol Geriatr. 2014;59(2):227–33.CrossRefPubMedGoogle Scholar
  3. 3.
    Artz MB, Harnack LJ, Duval SJ, Armstrong C, Arnett DK, Luepker RV. Use of nonprescription medications for perceived cardiovascular health. Am J Prev Med. 2006;30(1):78–81.CrossRefPubMedGoogle Scholar
  4. 4.
    Açıkgöz SK, Açıkgöz E, Topal S, Okuyan H, Yaman B, Er O, Şensoy B, Balcı MM, Aydoğdu S. Effect of herbal medicine use on medication adherence of cardiology patients. Complement Ther Med. 2014;22(4):648–54.CrossRefPubMedGoogle Scholar
  5. 5.
    Krasuski RA, Michaelis K, Eckart RE. The cardiovascular patient's perceptions of complementary and alternative medicine. Clin Cardiol. 2006;29(4):161–4.CrossRefPubMedGoogle Scholar
  6. 6.
    Albert NM, Rathman L, Ross D, Walker D, Bena J, McIntyre S, Philip D, Siedlecki S, Lovelace R, Fogarty AM, Maikut B. Predictors of over-the-counter drug and herbal therapies use in elderly patients with heart failure. J Card Fail. 2009;15(7):600–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Pharand C, Ackman ML, Jackevicius CA, Paradiso-Hardy FL, Pearson GJ. Use of OTC and herbal products in patients with cardiovascular disease. Ann Pharmacother. 2003;37(6):899–904.CrossRefPubMedGoogle Scholar
  8. 8.
    Dal Corso E, Bondiani AL, Zanolla L, Vassanelli C. Nurse educational activity on non-prescription therapies in patients with chronic heart failure. Eur J Cardiovasc Nurs. 2007;6(4):314–20.CrossRefPubMedGoogle Scholar
  9. 9.
    Gardiner P, Graham RE, Legedza AT, Eisenberg DM, Phillips RS. Factors associated with dietary supplement use among prescription medication users. Arch Intern Med. 2006;166(18):1968–74.CrossRefPubMedGoogle Scholar
  10. 10.
    Hensrud DD, Engle DD, Scheitel SM. Underreporting the use of dietary supplements and nonprescription medications among patients undergoing a periodic health examination. Mayo Clin Proc. 1999;74(5):443–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Kabbara WK, Dimassi H, Sheikh-Taha M. Patterns of pain medication use in older individuals with cardiovascular disease. Curr Med Res Opin. 2018;34(5):931–4.CrossRefPubMedGoogle Scholar
  12. 12.
    Goh LY, Vitry AI, Semple SJ, Esterman A, Luszcz MA. Self-medication with over-the-counter drugs and complementary medications in South Australia's elderly population. BMC Complement Altern Med. 2009;9(1):42.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Stys T, Stys A, Kelly P, Lawson W. Trends in use of herbal and nutritional supplements in cardiovascular patients. Clin Cardiol. 2004;27(2):87–90.CrossRefPubMedGoogle Scholar
  14. 14.
    Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300(24):2867–78.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Alherbish A, Charrois TL, Ackman ML, Tsuyuki RT, Ezekowitz JA. The prevalence of natural health product use in patients with acute cardiovascular disease. PLoS One. 2011;6(5):e19623.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Honarbakhsh S, Schachter M. Vitamins and cardiovascular disease. Br J Nutr. 2008;101(8):1113–31.CrossRefPubMedGoogle Scholar
  17. 17.
    Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, Buring JE, Manson JE. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA. 2008;299(17):2027–36.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson JE, Glynn RJ, Gaziano JM. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' health study II randomized controlled trial. JAMA. 2008;300(18):2123–33.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet. 2003;361(9374):2017–23.CrossRefPubMedGoogle Scholar
  20. 20.
    Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL Jr, Valanis B, Williams JH Jr, Barnhart S. Effects of a combination of beta carotene and vitamin a on lung cancer and cardiovascular disease. N Engl J Med. 1996;334(18):1150–5.CrossRefPubMedGoogle Scholar
  21. 21.
    FDA (2017, 11) Biotin (Vitamin B7): Safety Communication - May Interfere with Lab Tests. Retrieved from: https://www.fda.gov/medicaldevices/safety/alertsandnotices/ucm586505.htm. Accessed 24 Nov 2018.
  22. 22.
    Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med. 2008;168(11):1174–80.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D’Agostino RB, Wolf M, Vasan RS. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503–11.CrossRefPubMedGoogle Scholar
  24. 24.
    Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, Kinkeldei J, Boehm BO, Weihrauch G, Maerz W. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008;168(12):1340–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Anderson JL, May HT, Horne BD, et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol. 2010;106(7):963–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Pilz S, Verheyen N, Grübler MR, Tomaschitz A, März W, Vitamin D. cardiovascular disease prevention. Nat Rev Cardiol. 2016;13(7):404–17.CrossRefPubMedGoogle Scholar
  27. 27.
    Al Mheid I, Quyyumi AA. Vitamin D and cardiovascular disease: controversy unresolved. J Am Coll Cardiol. 2017;70(1):89–100.CrossRefPubMedGoogle Scholar
  28. 28.
    Singh S, Rao SS. Pharmacologic management of chronic constipation. Gastroenterol Clin N Am. 2010;39:509–27.CrossRefGoogle Scholar
  29. 29.
    DiPalma JA, vB Cleveland M, McGowan J, Herrera JL. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol. 2007;102(7):1436–41.CrossRefPubMedGoogle Scholar
  30. 30.
    Corazziari E, Badiali D, Bazzocchi G, Bassotti G, Roselli P, Mastropaolo G, Lucà MG, Galeazzi R, Peruzzi E. Long term efficacy, safety, and tolerabilitity of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. Gut. 2000;46(4):522–6.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Beers criteria update expert panel. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–46.CrossRefGoogle Scholar
  32. 32.
    Bueno H, Bardají A, Patrignani P, Martín-Merino E, García-Rodríguez LA. Use of non steroidal anti-inflammatory drugs and type specific risk of acute coronary syndrome. Am J Cardiol. 2010;105:1102–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Fanelli A, Ghisi D, Aprile PL, Lapi F. Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. Ther Adv Drug Saf. 2017;8(6):173–82.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Loya AM, González-Stuart A, Rivera JO. Prevalence of polypharmacy, polyherbacy, nutritional supplement use and potential product interactions among older adults living on the United States-Mexico border. Drugs & Aging. 2009;26(5):423–36.CrossRefGoogle Scholar

Copyright information

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  1. 1.Department of Pharmacy PracticeLebanese American UniversityByblosLebanon
  2. 2.Department of Pharmaceutical SciencesLebanese American UniversityByblosLebanon

Personalised recommendations